Crossmark

Can Pembrolizumab or Nivolumab be efficiently used against colorectal cancers with defective mismatch repair and high index of microsatellite instability?

Crossref DOI link: https://doi.org/10.1007/s12032-025-02849-4

Published Online: 2025-07-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

do Nascimento, Glauto Tuquarre Melo

Pereira, Irislene Costa

de Oliveira, Kynnara Gabriella Feitosa

Santos, Álina Mara Carvalho Pedrosa

do Nascimento, Maria Luisa Lima Barreto

Porto, Jhonatas Cley Santos

Torres-Leal, Francisco Leonardo

da Silva, Felipe Cavalcanti Carneiro

de Oliveira Ferreira, José Roberto

Ferreira, Paulo Michel Pinheiro

de Castro e Sousa, João Marcelo
License Information

Text and Data Mining valid from 2025-07-01

Version of Record valid from 2025-07-01
More Information

Article History

Received: 15 March 2025

Accepted: 4 June 2025

First Online: 1 July 2025

Declarations

:

: There are no conflicts of interest associated with this publication and there has been no financial support for this work that could have influenced its outcome.

: Not applicable.

: Not applicable.

Document is current

Any future updates will be listed below